drugset / Trial / NCT01605331

Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

NCT01605331 ↗

Phase 4 Completed 132 enrolled LG Life Sciences
NaSingle-groupOpen-labelTreatment

Summary

As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life. Patients, however, do have to tolerate daily injections of GH (rhGH).

Timeline

Start
2009-12
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human GH Protein / enzyme biologic 2 mg Subcutaneous

Indications